Loading
CH
China Health Group Ltd. Stock: price and insider trades · Hong Kong
HK·Mcap HK$367.6M
No insider purchase over the last 90 days. The latest, by Cao Xu, was filed 05 Feb 2026.
China Health Group Ltd.: what insiders have been doing
This page follows insider dealings at China Health Group Ltd. as filed with HKEX. From 20 October 2025 to 20 October 2026, the disclosure feed for China Health Group Ltd. logged 6 filings by 3 insiders.
On the market, 3 insiders bought (3 purchases) while 3 insiders sold (3 sales). The totals do not cover 6 filings with an undisclosed amount. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Among those who bought: 3 senior executives.
With 6 filings in twelve months, the company is more active than the median of 4 filings across the 1,323 companies we follow on the same exchange. Since 2017, the database holds 58 purchases and 4 sales by insiders of the company.
The clock since the last published purchase (5 February 2026) now reads 258 days. Between a trade and the moment it shows up on HKEX, the median delay is 7 days. This delay matters because a trade only becomes useful information once it is public.
In the same market, recent insider purchases at Sun Hung Kai Properties Ltd. and Xinyi Glass Holdings Ltd. also feature in our signals. This summary is built from HKEX disclosures alone and does not predict where the share price will go.
Insider Decl.
62
Thresholds
n/a
Buy Volume
€10M
58 ops. · all time
Sell Volume
€1M
4 ops. · all time
Who traded when
BuySaleChung Ho2 buys1 sale
Cao Xu1 buy1 sale
Ying Rensi1 buy1 sale
HUANG Lianhai1 buy
JIANG Xuejun1 buy
Wang Jingming1 buy
+2 other insiders
Since the insiders bought
- -40.0%Entry HK$0.45 · Close 16 Oct 2026 HK$0.27
- -40.0%Entry HK$0.45 · Close 16 Oct 2026 HK$0.27
- -40.0%Entry HK$0.45 · Close 16 Oct 2026 HK$0.27
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 24,197 of 26,281 companies
19.5
score / 100
Value21
Quality18
FCF yld-2.3%
Earn yld-18%
EV/EBITDA·
ROE-159%
Gross mgn24%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2026FY ended March 2026 · cache
HK$0.27
Analyst consensus
Income statement
RevenueHK$38.9M
Gross profitHK$9.2M24% margin
EBITDA-HK$63.7M-164% margin
Net income-HK$67.8M-116.6% margin
Valuation
P/Book7.0x
Beta-1.15
Balance sheet & cash
Market capHK$367.6M
Total debtHK$6.5M
Free Cash Flow-HK$8.4M
Debt / Equity8%
Profitability & ownership
ROE-158.9%
ROA-13.9%
% insiders68.3%
% institutions0.0%
Last declaration on 23 February 2026
Declarations62 total
1,338,000 sharesShareXHKGHKEX:DA20260223E00039
1,338,000 sharesShareXHKGHKEX:DA20260205E00178
Canonical exit: 3 May 2026 (T+90)
544,145 shares@ HK$0.10100.0% of flowShareXHKGHKEX:DA20251010E00583
Canonical exit: 4 Jan 2026 (T+90)
189,268 shares@ HK$0.10100.0% of flowShareXHKGHKEX:DA20251010E00584
Canonical exit: 4 Jan 2026 (T+90)
926,155 shares@ HK$0.104.7% of flowShareXHKGHKEX:DA20251010E00586
Canonical exit: 4 Jan 2026 (T+90)
510,000 shares@ HK$0.569915.9% of flowShareXHKGHKEX:DA20240821E00245
Canonical exit: 14 Nov 2024 (T+90)
4,000,000 sharesShareXHKGHKEX:DA20211028E00228
Canonical exit: 18 Jan 2021 (T+90)
25 of 62 declarations
About China Health Group Ltd.
Recent ranked signals on the same market
Purchases our model currently ranks for the recommendations list.
All recommendations